Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model

Efficacy of anti-LAG3 and anti-PD-1 combination checkpoint inhibitor therapy against head and neck squamous cell carcinoma in a genetically engineered mouse model

Head and neck squamous cell carcinoma (HNSCC) continues to be among the most common malignancies worldwide with limited treatment options for patients. Targeting the PD-1/PDL-1 axis is currently the only FDA approved immune checkpoint inhibitor treatment for HNSCC. Novel therapies targeting other pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Felipe F. Lamenza, Peyton Roth, Puja Upadhaya, Suvekshya Shrestha, Sushmitha Jagadeesha, Natalie Kazmierowicz, Natalie Horn, Hasan Pracha, Sonali Dasari, Steve Oghumu
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
LAG-3
PD-1
HNSCC
T cell
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2477872
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items